Reverse Rett's mission is to speed treatments and cures for Rett Syndrome and related MECP2 disorders by funding research that will have a practical and positive effect on the lives of those living with Rett Syndrome.
We fund research from basic science to developing new clinical treatments, and work to facilitate the translation of this work to clinical applications for children with Rett Syndrome and related MECP2 disorders.
Most of the funds we raise at Reverse Rett are invested in basic scientific research via our partner organization in the USA, the Rett Syndrome Research Trust (RSRT).
RSRT has an eminent Scientific Advisory Board (SAB) and research grants made by RSRT are subject to a world class peer review system with external reviewers, the SAB and then the RSRT Board being involved in the decision making progress.
We are also working to push forward our mission in the UK by supporting doctors who are doing clinical research and running progressive clinics for patients with Rett Syndrome. In the UK, the amount of funding provided for UK clinical research or improvements in UK clinical provision is very limited.
Reverse Rett does not intend to make any investments into basic science research other than through RSRT in the US.
However, for our UK work, we are currently working with the Association of Medical Research Charities (AMRC) to put in place an internal peer review process which will help us make the best possible objective and rational decisions re funding UK based clinical work.
We want to ensure that UK funding decisions made by Reverse Rett serve the long-term interests of Rett patients in the UK (and the rest of the world) and are in line with the objectives of the charity.